FIELD: medicine.
SUBSTANCE: present invention relates to the provision of vaccines which are specific for a patient's tumour and are potentially useful for immunotherapy of the primary tumour as well as tumour metastases. In one aspect, the present invention relates to a method for providing an individualised cancer vaccine comprising steps: (a) identifying cancer specific somatic mutations in a tumour specimen of a cancer patient to provide a cancer mutation signature of the patient; and (b) providing a RNA vaccine featuring the cancer mutation signature obtained in step (a). In a further aspect, the present invention relates to vaccines which are obtainable by said method.
EFFECT: individualised vaccines for cancer are disclosed.
19 cl, 21 dwg, 8 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PREDICTION OF IMMUNOGENICITY OF T-CELL EPITOPES | 2014 |
|
RU2724370C2 |
| INDIVIDUALIZED ANTI-TUMOR VACCINES | 2012 |
|
RU2779946C2 |
| METHODS FOR PREDICTION OF APPLICABILITY OF PROTEINS OR PROTEIN FRAGMENTS FOR IMMUNOTHERAPY | 2017 |
|
RU2782336C2 |
| METHODS OF PREDICTING THE APPLICABILITY OF DISEASE-SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPY | 2018 |
|
RU2799341C2 |
| DETERMINATION OF DOSE FOR IMMUNOTHERAPEUTIC AGENTS | 2017 |
|
RU2771717C2 |
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2018 |
|
RU2794945C2 |
| ANTIBODIES AGAINST CLAUDIN 18.2 FOR CANCER DIAGNOSIS | 2013 |
|
RU2661772C2 |
| ANTIGEN RECEPTORS AND THEIR APPLICATIONS | 2016 |
|
RU2792042C2 |
| IDENTIFICATION OF TUMOUR-ASSOCIATED ANTIGENS FOR DIAGNOSTICS AND THERAPY | 2013 |
|
RU2644686C2 |
| COMBINED THERAPY WITH CLAUDINE 18.2 ANTIBODIES FOR CANCER TREATMENT | 2014 |
|
RU2699549C2 |
